You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

progression free survival

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic Prostate Cancer Trial (Darolutamide, Radium-223)

Not yet recruiting
  • Metastatic Prostate Cancer
  • (no location specified)
Mar 6, 2023

Radiotherapy Combined With EGFR-TKI for Stage III EGFR Mutant

Completed
  • The Primary Study Metric is Progression-free Survival (PFS)
    • (no location specified)
    Jun 28, 2023

    Progression-free Survival Trial (Sovalteinib Solutumab Tegeo)

    Not yet recruiting
    • Progression-free Survival
    • Sovalteinib Solutumab Tegeo
    • (no location specified)
    Jul 24, 2023

    Overall Survival, Progression-free Survival, Cost Trial (Microwave Ablation)

    Completed
    • Overall Survival
    • +2 more
    • Microwave Ablation
    • (no location specified)
    Apr 1, 2023

    Meningioma, Meningioma Atypical, Anaplastic Meningioma Trial in Rome (Biological biomarker assessment)

    Recruiting
    • Meningioma
    • +2 more
    • Biological biomarker assessment
    • Rome, Italy
      Fondazione Policlinico Universitario A. Gemelli IRCCS
    Mar 29, 2023

    Progression Free Survival(PFS) Trial (Toposide capsules combined with anrotinib and Emvolizumab group)

    Not yet recruiting
    • Progression Free Survival(PFS)
    • Toposide capsules combined with anrotinib and Emvolizumab group
    • (no location specified)
    Jan 13, 2023

    Pancreatic Cancer, Thromboembolism Trial in Athens (Innohep, Chemotherapy: Gemcitabine + Nab-Paclitaxel)

    Recruiting
    • Pancreatic Cancer
    • Thromboembolism
    • Innohep
    • Chemotherapy: Gemcitabine + Nab-Paclitaxel
    • Athens, Attiki, Greece
    • +1 more
    Mar 28, 2022

    Bladder Cancer, Bladder Urothelial Carcinoma Trial in Toronto (re-TURBT, 6 weeks BCG instillation)

    Terminated
    • Bladder Cancer
    • Bladder Urothelial Carcinoma
    • re-TURBT
    • 6 weeks BCG instillation
    • Toronto, Ontario, Canada
      University Health Network
    Apr 12, 2022

    Progression Free Survival, Overall Survival, Maintenance Trial (Ixazomib DX/Lenalidomide DX)

    Not yet recruiting
    • Progression Free Survival
    • +2 more
    • Ixazomib DX/Lenalidomide DX
    • (no location specified)
    Jul 27, 2022

    Breast Cancer Stage IV Trial in Mansoura (comparing both arms as regard the objective response rate, toxicity profile, quality

    Recruiting
    • Breast Cancer Stage IV
    • comparing both arms as regard the objective response rate, toxicity profile, quality of life, progression free survival
    • Mansoura, Dakahlia, Egypt
      Oncology center mansoura university
    Jan 1, 2023

    free Survival and Evaluate Participant Experience for Metastatic

    Active, not recruiting
    • Anaplastic Lymphoma Kinase-positive
    • Carcinoma Non-small-cell Lung
    • Maynard, Massachusetts
      EmpiraMed, Inc.
    Feb 28, 2022

    Glioblastoma Trial in Toronto (Exercise)

    Completed
    • Glioblastoma
    • Exercise
    • Toronto, Ontario, Canada
      Princess Margaret Hospital, University Health Network
    Apr 13, 2022

    Chromosomal Instability in Ovarian Cancer

    Recruiting
    • Epithelial Ovarian Cancer
    • +7 more
    • Testing for chromosomal instability (CIN)
    • Beijing, Beijing, China
      Lei Li
    Mar 26, 2022

    NSCLC Trial in Rozzano (Pemetrexed/Carboplatin, Gemcitabine)

    Terminated
    • NSCLC
    • Rozzano, Milan, Italy
      Istituto Clinco Humanitas
    Sep 8, 2022

    Colorectal Cancer, Chinese Herbal Medicine, Progression-free Survival Trial in China (Brucea javanica oil emulsion injection,

    Recruiting
    • Colorectal Cancer
    • +3 more
    • Brucea javanica oil emulsion injection
    • The best supportive treatment
    • Guangzhou, Guangdong, China
    • +3 more
    Jun 1, 2023

    PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer

    Recruiting
    • Immune Checkpoint Inhibitors
    • +9 more
    • Radiotherapy for targeted lesions and PD-1 antibody
    • Beijing, Beijing, China
      Lei Li
    Apr 1, 2022

    HRD and Resistance to PAPPi in EOC Patients

    Recruiting
    • Epithelial Ovarian Cancer
    • +6 more
    • Testing of homologous recombination deficiency
    • Beijing, Beijing, China
      Lei Li
    Mar 26, 2022

    Waldenstrom's Disease, Prognostic Index Trial in France

    Not yet recruiting
    • Waldenstrom's Disease
    • Prognostic Index
      • Amiens, France
      • +14 more
      Jun 12, 2023

      Multiple Myeloma Trial in Little Rock (Carfilzomib, Thalidomide, Dexamethasone)

      Active, not recruiting
      • Multiple Myeloma
      • Little Rock, Arkansas
        University of Arkansas for Medical Sciences
      Sep 1, 2022

      Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival Trial in Wuhan (Surufatinib)

      Recruiting
      • Hepatocellular Carcinoma; Targeted Therapy; Progression-free Survival
      • Wuhan, Hubei, China
        Zhongnan Hopital of Wuhan University
      Mar 8, 2022

      Colorectal Cancer, Oligometastatic Disease Trial in Australia (Local Ablative Therapy, Standard first-line systemic treatment)

      Recruiting
      • Colorectal Cancer
      • Oligometastatic Disease
      • Local Ablative Therapy
      • Standard first-line systemic treatment
      • Albury, New South Wales, Australia
      • +8 more
      May 15, 2023

      Metastatic Colorectal Cancer Trial in Marseille (Oncogramme results available, Oncogramme results unavailable)

      Not yet recruiting
      • Metastatic Colorectal Cancer
      • Oncogramme results available
      • Oncogramme results unavailable
      • Marseille, France
        Hôpital Saint Joseph Marseille
      Mar 18, 2022

      Progression-free Survival, Gastrointestinal Stromal Tumor, Neoadjuvant Trial in Hangzhou (Imatinib)

      Recruiting
      • Progression-free Survival
      • +2 more
      • Hangzhou, Zhejiang, China
        The First Affiliated Hospital, College of Medicine, Zhejiang Uni
      Oct 9, 2021

      Myeloid Malignancies, Lymphoid Malignancies Trial in Durham (NK Cell enriched-DLI only, NK-DLI + DUK-CPG-001)

      Recruiting
      • Myeloid Malignancies
      • Lymphoid Malignancies
      • NK Cell enriched-DLI only
      • NK-DLI + DUK-CPG-001
      • Durham, North Carolina
        Duke University Health System
      Mar 8, 2022

      Colorectal Cancer, Circulating Tumor DNA, Adjuvant Chemo Trial in Denmark (Capox (or FOLFOX) including flouropyrimidine and

      Recruiting
      • Colorectal Cancer
      • +3 more
      • Capox (or FOLFOX) including flouropyrimidine and oxaliplatin combination chemotherapy
      • Intensified Follow-up Schedule
      • Aalborg, Denmark
      • +3 more
      Feb 24, 2022